A Cochrane meta-analysis of 22 studies with nearly 2,000 participants found intermittent fasting is not particularly effective for weight loss in obese or overweight adults and does not differ significantly from standard dietary advice. Experts note it remains an alternative at least as effective as classic calorie restriction, but more long-term trials are needed.
A study in Life Metabolism shows that a single post-meal blood biomarker, 1-hour postprandial SPARC, predicts who benefits most from a Mediterranean diet. Lower baseline SPARC-1H levels were linked to greater improvements in insulin resistance and glucose control in a six-month trial.
New research shows GLP-1 receptor agonists are associated with reduced asthma exacerbation risk in overweight, obese, and morbidly obese patients without diabetes, with risk reductions of 14.6%, 12.2%, and 13.3% respectively. The findings were presented at the 2026 AAAAI Annual Meeting.
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
A Cochrane review found intermittent fasting did not beat standard diet advice for weight loss. A separate trial found it matched calorie restriction but felt less restrictive. Experts advise a case-by-case approach given limited evidence.
New research: any cardiometabolic risk factor justifies MASLD screening in overweight adults, and MASLD independently worsens sepsis, bleeding, and other outcomes in hospitalized Crohn's disease patients.
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
The UK MHRA approved oral semaglutide (Wegovy) as the first GLP-1 weight loss tablet on 11 June 2026. A new report links high-dose tirzepatide to anhedonia, and data show bariatric surgery declining sharply as GLP-1 use surges.
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07781150 |
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07775404 |
A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus |
NOT_YET_RECRUITING | PHASE3 |
| NCT07770893 |
Acupoint Catgut Embedding With Laser Acupuncture for Weight Loss in Adults With Obesity |
NOT_YET_RECRUITING | NA |
| NCT07770841 |
Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight |
RECRUITING | PHASE3 |
| NCT07767175 |
A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07765511 |
A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes |
NOT_YET_RECRUITING | PHASE1 |
| NCT07757087 |
A Research Study to See How NNC0487-0111 Affects the Body's Energy Use After a Weight Loss in Adults Living With Obesity, Compared to a Low-calorie Diet or Placebo |
RECRUITING | PHASE1 |
| NCT07756177 |
Guangzhou Preterm and Term Birth Cohort Study |
ACTIVE_NOT_RECRUITING | |
| NCT07754474 |
A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or Obesity |
NOT_YET_RECRUITING | PHASE1 |
| NCT07752979 |
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities |
NOT_YET_RECRUITING | PHASE2 |
